Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CD19-STAR-T for B Cell Malignancies
NCT03953599Phase 1Completed
- Sponsor
- Lu Daopei Hospital
- Start
- Jul 2019
- Primary completion
- Jul 2021
- Modality
- CAR-T Cells
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of HXYT-001 in B-cell malignancy, sponsored by Lu Daopei Hospital. Primary endpoints: Percentage of adverse events at 6 months and Objective Remission Rate at 6 months. Started Jul 2019; status: completed.
02
Drugs
HXYT-001
03
Conditions
B-cell malignancy
Beyond the preview
Go deeper on NCT03953599.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03953599.